Skip to main content

Advertisement

Table 1 Niraparib potentiates the effects of SN-38 in MSI and MSS cell lines

From: Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status

   7 day EC50 (nM) Combination EC50 (shift of SN-38 EC50 in presence of Niraparib)
     Niraparib
  Cell line Niraparib SN-38 125 nM 250 nM 1000 nM
MSI DLD1 3560 3.63 0.992 1.67 1.68
HCT8 2130 3.60 2.07 1.54 1.35
HCT15 1685 3.77 3.47 3.44 1.73
HCT116 6915 0.180 0.125 0.155 0.0991
LOVO 2010 3.43 2.3 3.53 2.4
LS174T 1310 0.331 0.257 0.208 0.231
LS180 3730 0.474 0.399 0.395 0.389
LS411N 1875 3.57 1.21 1.11 0.729
RKO 1870 0.958 0.593 0.778 0.184
RKOE6 1270 0.730 0.426 0.422 0.464
SNUC2A >10000 3.23 3.04 2.72 2.52
SW48 >10000 1.79 0.886 0.762 0.598
MSS COLO205 1990 1.57 0.572 0.475 0.531
HT29 6880 4.29 3.07 3.64 1.75
NCI-H-508 >10000 3.63 1.70 3.31 1.41
SK-CO-1 1090 0.416 0.178 0.334 0.143
SW403 >10000 3.39 1.14 1.87 0.387
SW480 >10000 29.0 11.9 11.6 8.7
SW620 552 5.91 3.62 UR UR
SW837 >10000 UR UR UR UR
SW948 7195 6.67 3.85 4.47 2.80
SW1116 >10000 UR UR UR UR
SW1417 >10000 27.7 29.2 28.3 31.0
SW1463 >10000 26.4 22.2 UR UR
T84 1460 1.01 0.491 0.352 0.210
  1. 7 day EC50 data for niraparib alone, SN-38 alone, and the combination EC50 at 125, 250 and 1000 nM of niraparib in a panel of 25 MSI and MSS CRC cell lines . The niraparib EC50 values are the average of n = 2 from previous experiments. The SN-38 EC50 values reported are for n = 1 for the experiment done on that day. Values listed under 125, 250, and 1000nM niraparib are the EC50 values for SN-38 in the presence of 125, 250 or 1000 nM niraparib (combination EC50). EC50 data was calculated using the inflection point of the curve in a 4 parameter fit in SoftMax Pro 5.2. UR indicates that the data is unreportable due to an inadequate curve.